Scilex Holding Company’s Post

If you wish to sequence anything, here is an unmissable opportunity to avail. Diverse genomics services! And all at 15 percent off for 150 days, in celebration of our 150 sequencing runs of #IlluminaMiseq @Mibiome miBiome Therapeutics LLP #miBiome #mibiomeTherapeutics #GenomicsForAll Services include, but not limited to: #WholeGenome #Microbiome #Transcriptome #Metagenome #Epigenome #Exome #TransplantGenomics #InfectiousDiseaseGenomics #OncologyGenomics #TuberculosisGenomics (TB) #CoronavirusGenomics (COVID) #RespiratoryDiseaseGenomics #HumanPapilommaVirusGenomics (HPV) #ReproductiveHealthGenomics #GutHealth: #miGQ #OralHealth: Microbiome #SkinHealth: Microbiome #VaginalHealth: Microbiome #InfantHealth: Microbiome If you can imagine anything more, include in comments and we will try our best to include that. Thanks, Scientifically yours, Dr. Gautam Das, Ph.D.

An exclusive presentation on Day 2 of the 7th Alcor Drug Discovery Platform featuring Raphaël G. Ognar, MSc MBA, CEO & Founder of NKILT Therapeutics, Inc. Raphaël, also the Chairman for Day 2, will provide a comprehensive update on the development of the unique CIR™ (Chimeric ILT-Receptor) technology. Gain insights into the latest data in AML and solid tumors, with a special focus on allogeneic and off-the-shelf technologies aimed at broadening treatment options for more patients. Don't miss this opportunity to stay at the forefront of innovative therapies! #AlcorDrugDiscovery #ADDP2024 #Innovation #LifeSciencesSummits #DrugDiscovery #PreclinicalSummits #USADrugDiscoverySummits

Halia Therapeutics, Inc.'s and Biolexis Therapeutics, Inc.'s partnership have identified a novel brain-penetrant small molecule candidate targeting NLRP3-driven neuroinflammation by leveraging Biolexis’ MolecuLern™ AI-enabled approach. This milestone represents a significant advancement in treatments for neuroinflammatory disorders, including Parkinson’s. #HaliaTherapeutics #BiolexisTherapeutics #BioUtah #UtahLifeSciences https://ow.ly/Jqow50SSyf2

We are pleased to share Medicenna President and CEO Fahar Merchant's presentation of the Company's clinical updates on MDNA11 at the Oncology Innovation Forum last month, ahead of the American Society of Clinical Oncology 2024 Meeting. MDNA11, being evaluated in the Phase 1/2 ABILITY-1 Study, is the only non-alpha beta-enhanced IL-2 immunotherapy in clinical development. MDNA11 continues to demonstrate its best-in-class potential with differentiated deep and durable single agent activity in patients with advanced solid tumors who have failed checkpoint therapy. Sachs Associates video below accompanies the presentation on MDNA11. Read the full release for more information: https://lnkd.in/dR44hYaW #Immunotherapy #Oncology #Biotech #ClinicalTrial #AdvancedTumors

$MDNAF $MDNA.to We expect to provide a comprehensive data-set on monotherapy from MDNA11 dose-expansion trial And some topline data on combo trial with #Ketruda Finally Sachs shared another great presentation by Dr. Fahar, MDNA's CEO at the 10th Annual Oncology Innovation Forum!

Are you attending? Please look for our poster: "Critical Path Institute Expands Data Analytics to Mitochondrial and Inherited Metabolic Diseases" Wellcome Connecting Science Learning and Training Amanda Klein mitoworld.org Critical Path Institute (C-Path) #leighsyndrome #mitochondrialdisease

Missed out on this year's #ASMS conference? That doesn’t mean you have to miss out on the exciting science we shared! Check out this poster presented by Jeremiah Bowers, based on a collaboration with MOMA Therapeutics.      By leveraging cutting-edge proteomic technologies and mass spectrometry workflows developed by Momentum, Bowers and colleagues were able to identify and characterize several covalent cysteine modifiers active against cancer-driving helicases. Their research demonstrates the power of mass spec covalent binding screening, modification mapping, and occupancy calculations in taking a project from screening to hit characterization with unmatched efficiency.      Want to learn more about this project? Request the full poster here: https://lnkd.in/e6GFCEvW      #CancerResearch #DrugDiscovery #RapidFireMS, #OrbitrapAscend #Covalent #Chemoproteomics #Chemicalbiology

Rob Etherington, our CEO, discusses innovation, regulatory, and investor challenges and opportunities in the #raredisease therapeutics market with Mike Ward of Clarivate. “We’ve seen regulatory flexibility start to occur for rare diseases and it is a godsend to the patients. More needs to be done… Rare diseases are important fights that we must continue every day,” says Rob. Tune in to hear Rob’s insights on rare disease therapies as Clene Nanomedicine, Inc. works to #EndALS: https://bit.ly/3VO0HQB

Imagine what you could do with 40% more cells after every isolation… Make it a reality with Akadeum's Alerion Microbubble Cell Separation System and our Human T Cell Leukopak Isolation Kit. Find out how Poseida Therapeutics is benefitting from the Alerion in this Case Study: https://hubs.li/Q02FVWDc0 #morecells #akadeum #celltherapy #cellisolation

#AACR2024 is just around the corner! We are delighted to announce that we will be presenting a poster (abstract No. 6069) featuring our oral, small molecule #BTK #degrader #UBX_303_1 for patients with relapsed/refractory B-cell malignancies. If you are attending #AACR2024, be sure to stop by and meet the #Ubix Therapeutics team. Learn more about our preclinical data and our plan for phase 1 clinical trial of #UBX_303_1. ㆍAbstract Number: 6069 ㆍDate & Time: Tuesday Apr 9, 2024, 1:30 PM - 5:00 PM ㆍLocation: Poster Section 30, Poster Board Number 28 ㆍTitle: Discovery and preclinical development of orally bioavailable potent BTK degrader, and its early clinical development for the treatment of relapsed and refractory B-cell malignancies